With the derivation of hES cells and the demonstration of their pluripotency in vivo, cell-based therapy of human degenerative diseases becomes a realistic possibility. However, little current evidence shows that these cells will efficiently and permanently ameliorate disease conditions without the formation of unwanted cell types or without the proliferation of desirable phenotypes in the wrong location. Our present study on the in vitro differentiation of monkey ES cells into NPCs as well as putative neurons and glial cell phenotypes represents the first step in establishing a nonhuman primate model for translational research. Ideally, such preclinical studies will establish a basis for the efficient and safe treatment of neurodegenerative diseases with ES cells or their derivatives. buy allegra online
The protocol employed was a modification of experimentation conducted in the mouse, in which more than 80% of NPCs expressed nestin, a marker of neuroepithelial progenitor cells, after selection in serum-free medium and proliferation with FGF-2. Further differentiation and characterization of these cells showed that more than 60% of the population expressed the neuronal marker, MAP-2, after withdrawal of FGF-2. With monkey ES cells, approximately 60% of expanded NPCs expressed nestin (66%) or musashi! (55%), another neurolineage marker, with approximately 45% of the cell population expressing markers of mature neurons after NPC differentiation into neural lineages.